LETTER TO THE EDITOR: AstraZeneca committed to patient access

I think I speak for many at AstraZeneca who come to work every day to help patients lead longer, healthier lives when I share I was disheartened to see a letter questioning our dedication. (“Here’s where to start in fighting the drug war.”, June 6)

AstraZeneca reached out to support the author on several occasions. While we are disappointed our efforts were not to his satisfaction, I am proud of the support we offer patients.

AstraZeneca is committed to patient access. For over 35 years, we’ve helped qualified patients through one of the longest-standing assistance programs in industry, AZ&ME, providing AstraZeneca medicines at no cost. Over the past 10 years, we’ve helped over 4 million patients in the US.

While AZ&ME was designed for needy patients, we offer additional programs and services. After our medicines are prescribed, we provide commercially insured patients and providers reimbursement support and connections to affordability programs.

We also offer copay savings programs to help eligible, commercially insured patients reduce copay costs, and we’re exploring ways to further assist patients.

We recognize many patients are facing challenges with out-of-pocket costs. This is an important issue. That’s why beyond our programs, we’re collaborating to find solutions to challenges we collectively face in ensuring patient access to innovative treatments.

Ruud Dobber
President, AstraZeneca U.S. and Executive Vice President, North America

Facebook Comment